Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

1,043

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

January 30, 2020

Study Completion Date

February 15, 2020

Conditions
Urinary Tract Infections
Interventions
DRUG

cefepime/AAI101 combination

cefepime 2 g / AAI101 500 mg

DRUG

Piperacillin/tazobactam

piperacillin 4 GM / tazobactam 500 MG

Trial Locations (24)

2300

MHAT Rahila Angelova AD, Pernik, Pernik

3200

Bugat Pal Korhaz, Gyöngyös

4600

Unimed Adjara - Kutaisi oncological centre, Kutaisi

6850

Clinical Projects Research, Worcester

8003

Hospital del Mar, Department of Infectious Disease, Barcelona

10000

"University Hospital for Infectious Diseases Dr. Fran Mihaljevic Department for general infectious diseases", Zagreb

11000

Clinical Hospital Center Zvezdara, Belgrade

14034

Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology, Chernihiv

15036

Clinica Internacional - Sede San Borja, Lima

33615

Florida Urology Partners, Tampa

51014

Tartu University Hospital, Tartu

59701

Mercury Street Medical, Butte

63110

Washington University School of Medicine, St Louis

76231

Republican Siauliai caunty hospital, Šiauliai

87131

University of New Mexico Health Sciences Center, Albuquerque

90122

Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s., Malacky

90620

Southbay Pharma Research, Buena Park

92804

St. Josephs Clinical Research, Anaheim

196143

Scientific Research Center Eco-Safety, Saint Petersburg

224027

Brest Regional Hospital, Brest

B1706FWM

HIGA Dr Ramon Carrillo, Buenos Aires

LV-1006

Uroklinika, LLC, Riga

CP. 94290

Centro Especializado en Investigación Clínica S.C., Boca del Río

02-507

Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii, Warsaw

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Allecra

INDUSTRY